Yesid Alvarado - Valero, M.D.

Peer-Reviewed Articles

1. Loges, S, Heuser, M, Chromik, J, Sutamtewagul, G, Kapp-Schwörer, S, Crugnola, M, Di Renzo, N, Lemoli, RM, Mattei, D, Fiedler, W, Alvarado, Y, Ben-Batalla, I, Waizenegger, JS, Rieckmann, LM, Janning, M, Collienne, M, Imbusch, CD, Beumer, N, Micklem, DR, H Nilsson, L, Madeleine, N, McCracken, N, Oliva, C, Gorcea-Carson, C, Gjertsen, BT. Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40122885.
2. DiNardo, C, Marvin-Peek, J, Loghavi, S, Takahashi, K, Issa, GC, Jen, WY, Daver, N, Reville, PK, Short, NJ, Sasaki, K, Mullin, JK, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Abbas, HA, Hammond, DE, Haddad, FG, Bravo, GM, Chien, KS, Yilmaz, M, Kornblau, SM, Jabbour, EJ, Ravandi-Kashani, F, Kadia, TM, Garcia-Manero, G, Konopleva, M, Kantarjian, HM. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML. Journal of Clinical Oncology 43(24):2692-2699, 2025. e-Pub 2025. PMID: 40513054.
3. Senapati, J, Kantarjian, HM, Kadia, TM, Kekedjian, J, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Bravo, GM, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Manero, GG, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16), 2025. e-Pub 2025. PMID: 40772501.
4. Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia, 2025. e-Pub 2025. PMID: 40813623.
5. Alvarado, Y, Cook, RJ, Dinner, S, Keng, MK, Begna, K, Javidi-Sharifi, N, Abedin, S, Al Malki, MM, Bhatt, VR, Rajagopalan, P, Tang, M, Wiley, SE, Ghalie, R, Davids, MS. The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia. Blood Neoplasia 2(3), 2025. e-Pub 2025. PMID: 40809193.
6. Goulart, H, Kantarjian, HM, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Pemmaraju, N, Alvarado, Y, Atluri, H, Yilmaz, M, Haddad, FG, Marx, K, Rausch, C, Loghavi, S, Jain, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia. Cancer 131(8), 2025. e-Pub 2025. PMID: 40193193.
7. DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
8. Cortes, JE, Kim, DW, Saikia, T, Khattry, N, Rathnam, K, Alvarado, Y, Hannah, G, Tantravahi, SK, Apperley, JF, Charbonnier, A, Garcia-Gutierrez, V, Lucchesi, A, Dima, D, Illés, Á, Popov, VM, Abruzzese, E, Nag, A, Apte, S, Badar, T, Yao, SL, Saxena, U, Sreenivasan, J, Inamdar, S, Chimote, G, Nicolini, FE. Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy. The Lancet Haematology 12(3):e201-e213, 2025. e-Pub 2025. PMID: 39929221.
9. Kantarjian, HM, Short, NJ, Jain, N, Haddad, FG, Kadia, TM, Yilmaz, M, Ferrajoli, A, Sasaki, K, Alvarado, Y, Pemmaraju, N, Senapati, J, Garris, R, Ravandi-Kashani, F, Jabbour, EJ. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. American journal of hematology 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
10. Davids, MS, Brander, D, Alvarado, Y, Diefenbach, CS, Egan, DN, Dinner, S, Javidi-Sharifi, N, Al Malki, MM, Begna, K, Bhatt, VR, Abedin, S, Cook, RJ, Collins, M, Roleder, C, Dominguez, EC, Rajagopalan, P, Wiley, SE, Ghalie, R, Danilov, AV. A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/ refractory acute myeloid leukemia and B-cell malignancies. Blood Advances 9(4):820-832, 2025. e-Pub 2025. PMID: 39705540.
11. Davids, MS, Brander, D, Alvarado, Y, Diefenbach, CS, Egan, DN, Dinner, S, Javidi-Sharifi, N, Al Malki, MM, Begna, K, Bhatt, VR, Abedin, S, Cook, RJ, Collins, M, Roleder, C, Dominguez, EC, Rajagopalan, P, Wiley, SE, Ghalie, R, Danilov, AV. A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/ refractory acute myeloid leukemia and B-cell malignancies. Blood Advances 9(4):820-832, 2025. e-Pub 2025. PMID: 39705540.
12. Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
13. Kantarjian, H, Short, NJ, Haddad, FG, Jain, N, Huang, X, Montalban-Bravo, G, Kanagal-Shamanna, R, Kadia, TM, Daver, N, Chien, KS, Alvarado, Y, Garcia-Manero, G, Issa, GC, Garris, R, Nasnas, C, Nasr, L, Ravandi, F, Jabbour, EJ. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. Journal of Clinical Oncology 42(36):4246-4251, 2024. e-Pub 2024. PMID: 39028925.
14. Bataller Torralba, A, Kantarjian, H, Bazinet, A, Kadia, TM, Daver, N, DiNardo, CD, Borthakur, G, Loghavi, S, Patel, K, Tang, G, Sasaki, K, Short, NJ, Yilmaz, M, Issa, GC, Alvarado, Y, Montalban-Bravo, G, Maiti, A, Abbas, HA, Takahashi, K, Pierce, S, Jabbour, EJ, Garcia-Manero, G, Ravandi, F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
15. Jabbour, EJ, Haddad, FG, Sasaki, K, Carter, BZ, Alvarado, Y, Nasnas, C, Nasr, L, Masarova, L, Daver, N, Pemmaraju, N, Short, NJ, Skinner, J, Kadia, TM, Borthakur, G, Garcia-Manero, G, Ravandi-Kashani, F, Issa, GC, Andreeff, M, Kantarjian, HM. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
16. Urrutia, S, Bose, P, Alvarado, Y, Borthakur, G, Ravandi-Kashani, F, Daver, N, Pemmaraju, N, Jabbour, EJ, Takahashi, K, Kadia, TM, DiNardo, C, Kornblau, SM, Kanagal Shamanna, R, Huang, X, Bodden, K, Kantarjian, HM, Garcia-Manero, G. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML. Blood Neoplasia 1(2), 2024. e-Pub 2024.
17. Urrutia S, Bose P, Alvarado Y, Borthakur G, Ravandi F, Daver N, Pemmaraju N, Jabbour E, Takahashi K, Kadia T, DiNardo C, Kornblau S, Kanagal-Shamanna R, Huang X, Bodden K, Kantarjian H, Garcia-Manero G. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML. Blood Neoplasia 1(2):100008, 2024. e-Pub 2024. PMID: 40454402.
18. Bazinet, A, Kantarjian, HM, Bataller, A, Pemmaraju, N, Borthakur, G, Chien, KS, Alvarado, Y, Bose, P, Jabbour, EJ, Yilmaz, M, DiNardo, C, Issa, GC, Montalban Bravo, G, Short, NJ, Sasaki, K, Bull-Linderman, D, Daver, N, Garcia-Manero, G, Ravandi-Kashani, F, Kadia, TM. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction. The Lancet Haematology 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
19. Bazinet, A, Garcia-Manero, G, Short, NJ, Alvarado, Y, Bataller, A, Abuasab, T, Islam, R, Montalbano, K, Issa, GC, Maiti, A, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Montalban Bravo, G, Rausch, CR, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Huang, X, Kantarjian, HM, Ravandi-Kashani, F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia. The Lancet Haematology 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
20. Bataller, A, Montalban Bravo, G, Bazinet, A, Alvarado, Y, Chien, KS, Venugopal, S, Ishizawa, J, Hammond, DE, Swaminathan, M, Sasaki, K, Issa, GC, Short, NJ, Masarova, L, Daver, N, Kadia, TM, Colla, S, Qiao, W, Huang, X, Kanagal Shamanna, R, Hendrickson, S, Ravandi-Kashani, F, Jabbour, EJ, Kantarjian, HM, Garcia-Manero, G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia. The Lancet Haematology 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
21. Jabbour, EJ, Haddad, FG, Short, NJ, Senapati, J, Jain, N, Sasaki, K, Jorgensen, JL, Wang, SA, Alvarado, Y, Wang, X, DiNardo, C, Masarova, L, Kadia, TM, Garris, R, Ravandi-Kashani, F, Kantarjian, HM. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417-421, 2024. e-Pub 2024. PMID: 37879077.
22. Jen, WY, Sasaki, K, Rausch, CR, DiNardo, C, Kadia, TM, Yilmaz, M, Borthakur, G, Alvarado, Y, McCue, D, McCue, D, Kantarjian, HM, Ravandi-Kashani, F. Acute kidney injury in acute promyelocytic leukemia. Leukemia and Lymphoma 65(3):378-382, 2024. e-Pub 2024. PMID: 38054837.
23. Babakhanlou R, Ellie-Nader M, Alvarado Y. A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia. Ann Hematol 102(12):3427-3430, 2023. e-Pub 2023. PMID: 37713123.
24. Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
25. Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol 98(10):E281-E284, 2023. e-Pub 2023. PMID: 37515433.
26. Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk 23(10):742-748, 2023. e-Pub 2023. PMID: 37308342.
27. Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
28. Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J 13(1):148, 2023. e-Pub 2023. PMID: 37735426.
29. Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
30. Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol 16(1):73, 2023. e-Pub 2023. PMID: 37422688.
31. DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2023. PMID: 35973199.
32. Delgado A, Vera-Villalobos J, Paz JL, Lossada C, Hurtado-León ML, Marrero-Ponce Y, Toro-Mendoza J, Alvarado YJ, González-Paz L. Macromolecular crowding impact on anti-CRISPR AcrIIC3/NmeCas9 complex: Insights from scaled particle theory, molecular dynamics, and elastic networks models. Int J Biol Macromol:125113. e-Pub 2023. PMID: 37257544.
33. Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 16(1):44, 2023. e-Pub 2023. PMID: 37131217.
34. Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski RE, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia T, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours. Br J Haematol 201(3):e25-e29, 2023. e-Pub 2023. PMID: 36951293.
35. Senapati J, Abuasab T, Haddad FG, Ravandi F, Kadia T, DiNardo C, Daver N, Pemmaraju N, Alvarado Y, Brandt MA, Kantarjian H, Borthakur G. Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol 98(3):E53-E56, 2023. e-Pub 2023. PMID: 36565294.
36. González-Paz L, Lossada C, Hurtado-León ML, Fernández-Materán FV, Paz JL, Parvizi S, Cardenas Castillo RE, Romero F, Alvarado YJ. Intrinsic Dynamics of the ClpXP Proteolytic Machine Using Elastic Network Models. ACS Omega 8(8):7302-7318, 2023. e-Pub 2023. PMID: 36873006.
37. Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10(1):e24-e34, 2023. e-Pub 2023. PMID: 36402146.
38. Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol 9(12):e878-e885, 2022. e-Pub 2022. PMID: 36279879.
39. Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50?mg/day versus standard-dose dasatinib 100?mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
40. Borthakur G, Ravandi F, Patel K, Wang X, Kadia T, DiNardo C, Garcia-Manero G, Pemmaraju N, Jabbour EJ, Takahashi K, Ohanian M, Daver N, Alvarado Y, Brandt M, Pierce S, Kantarjian H. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol 97(11):1427-1434, 2022. e-Pub 2022. PMID: 36053747.
41. Kim, K, Ong, F, Montalban Bravo, G, Kanagal Shamanna, R, Kadia, TM, Jabbour, EJ, Alvarado, Y, Sasaki, K, Dong, XQ, Pierce, S, Bueso-Ramos, CE, Kantarjian, HM, Chien, KS, Garcia-Manero, G. MDS-406 Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia 22:S310, 2022. e-Pub 2022. PMID: 36163955.
42. Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S313-S314, 2022. e-Pub 2022. PMID: 36163960.
43. Haddad, FG, Kantarjian, HM, Short, NJ, Konopleva, M, Jain, N, Huang, X, Ravandi-Kashani, F, Wierda, WG, Borthakur, G, Sasaki, K, Issa, GC, Alvarado, Y, Pemmaraju, N, Garcia-Manero, G, Thankachan, J, Garris, R, Jabbour, EJ. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S204, 2022. e-Pub 2022. PMID: 36163747.
44. Ong, F, Kadia, TM, Short, NJ, Yilmaz, M, Alvarado, Y, Sasaki, K, Pierce, S, Garcia-Manero, G, DiNardo, C, Borthakur, G, Konopleva, M, Daver, N, Kantarjian, HM, Ravandi-Kashani, F. AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). Clinical Lymphoma, Myeloma and Leukemia 22:S258, 2022. e-Pub 2022. PMID: 36163855.
45. Venugopal, S, Kantarjian, HM, Maiti, A, Short, NJ, Montalban Bravo, G, Alvarado, Y, Chien, KS, Kanagal Shamanna, R, Pemmaraju, N, Daver, N, Kadia, TM, Borthakur, G, Jabbour, EJ, Garcia-Manero, G. MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia 22:S321, 2022. e-Pub 2022. PMID: 36163977.
46. Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. e-Pub 2022. PMID: 36163813.
47. Abuasab, T, Senapati, J, Kadia, TM, Ravandi-Kashani, F, DiNardo, C, Pemmaraju, N, Ohanion, M, Alvarado, Y, Kantarjian, HM, Borthakur, G. AML-325 Prognostic Impact of RAS and C-KIT Mutations (Single vs. Multiple) in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated With a Fludarabine, Cytarabine, and G-CSF (FLAG)– Based Regimen. Clinical Lymphoma, Myeloma and Leukemia 22:S235-S236, 2022. e-Pub 2022. PMID: 36163808.
48. Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S311, 2022. e-Pub 2022. PMID: 36163957.
49. Bazinet, A, Kantarjian, HM, Borthakur, G, Yilmaz, M, Bose, P, Jabbour, EJ, Alvarado, Y, Chien, KS, Pemmaraju, N, Takahashi, K, Short, NJ, Daver, N, Issa, GC, Jain, N, Bull-Linderman, D, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Sasaki, K, Ravandi-Kashani, F, Kadia, TM. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
50. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
51. Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, Short NJ, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian HM, Garcia-Manero G. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid 1(10):EVIDoa2200034, 2022. e-Pub 2022. PMID: 38319837.
52. Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol 97(9):1135-1141, 2022. e-Pub 2022. PMID: 35713551.
53. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
54. Alvarado YJ, Olivarez Y, Lossada C, Vera-Villalobos J, Paz JL, Vera E, Loroño M, Vivas A, Torres FJ, Jeffreys LN, Hurtado-León ML, González-Paz L. Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT. Comput Biol Chem 99:107692, 2022. e-Pub 2022. PMID: 35640480.
55. Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
56. Senapati J, Shoukier M, Garcia-Manero G, Wang X, Patel K, Kadia T, Ravandi F, Pemmaraju N, Ohanian M, Daver N, DiNardo C, Alvarado Y, Aldrich J, Borthakur G. Activity of Decitabine as Maintenance Therapy in Core Binding Factor Acute Myeloid Leukemia. Am J Hematol 97(5):574-582, 2022. e-Pub 2022. PMID: 35150150.
57. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma:1-10. e-Pub 2022. PMID: 35442137.
58. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma 62(14):3501-3505, 2021. e-Pub 2021. PMID: 34474640.
59. Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer 127(22):4213-4220, 2021. e-Pub 2021. PMID: 34343352.
60. Chien KS, Kim K, Nogueras-Gonzalez GM, Borthakur G, Naqvi K, Daver NG, Montalban-Bravo G, Cortes JE, DiNardo CD, Jabbour E, Alvarado Y, Andreeff M, Bose P, Jain N, Kadia TM, Huang X, Sheppard KB, Klingner-Winton C, Pierce SA, Dong XQ, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol 195(3):378-387, 2021. e-Pub 2021. PMID: 34340254.
61. Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
62. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
63. Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, DiNardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552-e561, 2021. e-Pub 2021. PMID: 34329576.
64. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
65. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
66. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
67. Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
68. Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
69. Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
70. Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
71. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
72. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
73. Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. e-Pub 2020. PMID: 33112940.
74. Issa GC, Kantarjian HM, Xiao L, Ning J Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
75. Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, DiNardo CD, Daver N, Short NJ, Alvarado Y, Cortes J, Kim C, Kelsh M, Katz A, Williams R, Yang Z, Mehta B, Kantarjian H. Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871-e882, 2020. e-Pub 2020. PMID: 32792304.
76. Sasaki K, Jabbour E, Naqvi K, Skinner J, Anderson K, Dellasala E S, Yilmaz M, Ferrajoli A, Bose P, Thompson A P, Alvarado Y, Jain N, Garcia- Manero G, Takahashi K, Burger A J, Borthakur G, Pemmaraju N, Khouri R, Paul S, Pierce A S, Cortes E J, Kantarjian M K. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. Blood 136(Suppl 1):3-5, 2020. e-Pub 2020.
77. Short N, Kantarjian M H, Ravandi F, Huang X, Ferrajoli A, Kadia M T, Thompson A P, Alvarado Y, Jain N, Yilmaz M, Khoury D J, Jorgensen L J, Sa WA, Kornblau M S, Konopleva M, Garcia - Manero G, Schroeder M H, Kwari M, Paul S, Nwakanme B, Loiselle C, Garris R, O'Brien M S, Jabbour E. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. 62nd Annual Meeting & Exposition. Blood 136(Suppl 1):9-11, 2020. e-Pub 2020.
78. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
79. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489-2492, 2020. e-Pub 2020. PMID: 32099037.
80. Garcia-Manero G, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma 61(8):1943-1953, 2020. e-Pub 2020. PMID: 32264726.
81. Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
82. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
83. Navada SC, Garcia-Manero G, Odchimar Reissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Demakos EP, Zbyszewski PS, Maniar M, Woodman RC, Fruchtman SM, Silverman LR. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leuk Res 94:106369, 2020. e-Pub 2020. PMID: 32442785.
84. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience with Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2020. PMID: 32035785.
85. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
86. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. e-Pub 2020. PMID: 32027746.
87. Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 126(1):67-75, 2020. e-Pub 2020. PMID: 31553487.
88. Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
89. Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. e-Pub 2019. PMID: 31724006.
90. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
91. Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma 18(9):1-7, 2019. e-Pub 2019. PMID: 30773968.
92. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1-8, 2019. e-Pub 2019. PMID: 30632841.
93. Strati P, Garcia-Manero G, Zhao C, Kadia T, Borthakur G, Konopleva M, Daver N, DiNardo CD, Short NJ, Yilmaz M, Naqvi K, Alvarado Y, Pierce SA, Cortes J, Bueso-Ramos C, Kantarjian H, Ravandi F. Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. Am J Hematol 94(7):E188-E190, 2019. e-Pub 2019. PMID: 30977182.
94. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
95. Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 19(3):142-148.e1, 2019. e-Pub 2019. PMID: 30635233.
96. Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 5(1), 2019. e-Pub 2019. PMID: 30709875.
97. Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol 37(1):96-102, 2019. e-Pub 2019. PMID: 30153704.
98. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2019. PMID: 30545576.
99. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
100. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
101. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
102. Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85, 2018. e-Pub 2018. PMID: 30245189.
103. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol 182(3):442-444, 2018. e-Pub 2018. PMID: 28616864.
104. Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740-2747, 2018. e-Pub 2018. PMID: 29723397.
105. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol 5(4):e136-e146, 2018. e-Pub 2018. PMID: 29550383.
106. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
107. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, Khoury JD, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Y A, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2018. PMID: 29047158.
108. Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32(1):241-244, 2018. e-Pub 2018. PMID: 28919634.
109. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol 140(1):30-39, 2018. e-Pub 2018. PMID: 30071517.
110. Numan Y, Alfayez M, Maiti A, Alvarado Y, Jabbour EJ, Ferrajoli A, Konoplev SN, Kantarjian HM, Bose P. First report of clinical response to Venetoclax in Early T-cell Precursor Acute Lymphoblastic Leukemia. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 31080940.
111. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
112. Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. Blood 130(13):1514-1522, 2017. e-Pub 2017. PMID: 28774880.
113. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(7):1659, 2017. e-Pub 2017. PMID: 28338082.
114. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, A A, Konopleva M, Ravandi F, Estey E, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(2):318-324, 2017. e-Pub 2017. PMID: 27795561.
115. Tang Z, Tang G, Wang SA, Lu X, Young KH, Bueso-Ramos CE, Alvarado Y, Medeiros LJ, Khoury JD. Simultaneous deletion of 3'ETV6 and 5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet 9:23, 2016. e-Pub 2016. PMID: 26925167.
116. Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer 120(14):2142-9, 2014. e-Pub 2014. PMID: 24737502.
117. Alvarado Y, Giles FJ, Swords RT. The PIM kinases in hematological cancers. Expert Rev Hematol 5(1):81-96, 2012. e-Pub 2012. PMID: 22272708.
118. Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC. Clinical Activity of Mammalian Target of Rapamycin Inhibitors in Solid Tumors. Targeted Oncology 6(2):69-94, 2011. e-Pub 2011.
119. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 1(117):982-91, 2011. e-Pub 2011. PMID: 20960502.
120. Vemulapalli S, Mita M, Alvarado Y, Sankhala K, Mita A. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Targeted Oncology 6(1):29-39, 2011. e-Pub 2011.
121. Alvarado Y, Swords R, Kelly KR, Giles J. Clinical activity of laromustine (Onrigin™) in hematologic malignancies. Expert Review of Hematology 2(5):481-488, 2009. e-Pub 2009.
122. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-18, 2009. e-Pub 2009. PMID: 19517462.
123. Alvarado Y, Kantarjian H, O’Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia- Manero G, Shan J, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients with Early Chronic Phase Chronic Myeloid Leukemia. Cancer 115(16):3709-18, 2009. e-Pub 2009.
124. Swords R, Y A, Giles F. The Current Status of Biphenotypic Leukemia. Myeloproliferative Disorders in Practice 2(2), 2008. e-Pub 2008.
125. Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 Study of XL119, a Rebeccamycin Analog, in Patients with Refractory Hematologic Malignancies. Cancer 113(2):360-6, 2008. e-Pub 2008. PMID: 18473351.
126. Alvarado Y, Cortes J. Emerging Role of Aurora Kinase inhibition in Chronic Myeloid Leukemia. Clinical Leukemia 1(6):325-327, 2007. e-Pub 2007.
127. Alvarado Y, Welch MA, Swords R, Bruzzi J, Schelette E, Giles F. Plasma Cell Granuloma: A Case Report of Multiple Lesions in the Lung and Review of the Literature. American Journal of Medical Sciences 334(5):402-6, 2007. e-Pub 2007.
128. Alvarado Y, Jumper C, Hardwicke F, D’Cunha N, Cobos E. Acquired Hemophilia: A Case Report of 2 Patients with Acquired Factor VIII Inhibitor Treated with Rituximab Plus a Short Course of Steroid and Review of the Literature. Clinical and Applied Thrombosis and Hemostasis 13(4):443-8, 2007. e-Pub 2007.
129. Alvarado Y, Welch M, Swords R, Bruzzi J, Schelette E, Giles F. Nelarabine Activity in Acute Biphenotypic Leukemia. Leukemia Research 31(11):1600-1603, 2007. e-Pub 2007.
130. Swords R, Y A, Giles F. Novel abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clinical Lymphoma Myeloma 7(3):S113-9, 2007. e-Pub 2007.
131. Apostolidou E, Swords R, Alvarado Y, Giles FJ. Treatment of Acute Lymphoblastic Leukemia: A New Era?. Drugs 67(15):2153-71, 2007. e-Pub 2007.
132. Angulo F, Y A, Chokesuwattanaskul W, Roongsritrong C. Troponin I Elevation in a patient with Acute Severe Bronchospasm. The American Journal of the Medical Sciences 329(6), 2005. e-Pub 2005.
133. Giles F, Fracasso P, Kantarjian H, Cortes J, Brown R, Verstovsek S, Alvarado Y, thomas D, Faderl S, Garcia - Manero G, Wright L, Samson T, Cahill A, Lambert P, Plunket W, Sznol M, DiPersio J, Gandhi V. Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Research 27(12):1077-1083, 2003. e-Pub 2003.
134. Tsimberidou AM, Kantarjian H, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O’Brien S, Albitar M, Keating MJ, Giles FJ. Fractionated Cyclophosphamide, Vincristine, Liposomal daunorubicin, and Dexamethasone plus Rituximab and Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF) Alternating with Methotrexate and cytarabine plus Rituximab and GM-CSF in Patients with Richter’s Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. Cancer 97(7), 2003. e-Pub 2003.
135. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles F. Pilot study of pegylated Interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemotherapy and Pharmacology 5(1):81-86, 2003. e-Pub 2003.
136. Alvarado Y, Tsimberidou AM, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, Idarubicin and Cytarabine combination regimen in patients with primary resistant or relapsed Acute Myeloid Leukemia. Cancer Chemotherapy and Pharmacology 5(1):87-90, 2003. e-Pub 2003.
137. Alvarado Y, Bellm LA, Giles FJ. Oral Mucositis: time for more studies. Hematology 7:281-289, 2002. e-Pub 2002.
138. Alvarado Y, Kantarjian H, Cortes JE, Apostolidou E, Bivins C, Giles FJ. Troxacitabine activity in extramedullary myeloid leukemia. Hematology 7(3):179-185, 2002. e-Pub 2002.

Review Articles

1. Paz JL, Loroño MA, González-Paz LA, Márquez E, Mora JR, Alvarado YJ. Stochastic Nature and Intramolecular Coupling in Optical Response Profiles: Critical Analysis through Semiclassical Models. ACS Omega 8(12):10690-10712, 2023. e-Pub 2023. PMID: 37008123.
2. Vemulapalli S, Mita A, Alvarado Y, Sankhala K, Mita M. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Target Oncol 6(1):29-39, 2011. e-Pub 2011. PMID: 21533543.
3. Swords R, Alvarado Y, Cortes J, Giles FJ. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Curr Hematol Malig Rep 2(2):83-8, 2007. e-Pub 2007. PMID: 20425355.
4. Alvarado Y, Giles FJ. Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs 12(2):271-84, 2007. e-Pub 2007. PMID: 17604501.
5. Swords R, Alvarado Y, Giles F. Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma 7 Suppl 3:S113-9, 2007. e-Pub 2007. PMID: 17382020.
6. Alvarado Y, Apostolidou E, Swords R, Giles FJ. Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia. Expert Opin Emerg Drugs 12(1):165-79, 2007. e-Pub 2007. PMID: 17355221.
7. Apostolidou E, Swords R, Alvarado Y, Giles FJ. Treatment of acute lymphoblastic leukaemia : a new era. Drugs 67(15):2153-71, 2007. e-Pub 2007. PMID: 17927282.
8. Tsimberidou AM, Alvarado Y, Giles FJ. The Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Therapy 2(4):437-48, 2002. e-Pub 2002. PMID: 12647987.

Abstracts

1. Sasaki K, Jabbour E, Naqvi K, Skinner J, Anderson K, Dellasala E S, Yilmaz M, Ferrajoli A, Bose P, Thompson A P, Alvarado Y, Jain N, Garcia- Manero G, Takahashi K, Burger A J, Borthakur G, Pemmaraju N, Khouri R, Paul S, Pierce A S, Cortes E J, Kantarjian M K. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. 62nd Annual Meeting & Exposition. Blood 136(Suppl 1):3-5, 2020. e-Pub 2020.
2. Morita K, Naqvi K, Montalban Bravo G, Thompson A P, Takahashi K, Alvarado Y, Jabbour E, Kantarjian M H, Garcia - Manero G. Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). 62nd Annual Meeting & Exposition.. Blood 136(Suppl 1):39-40, 2020. e-Pub 2020.
3. Short N, Kantarjian M H, Ravandi F, Huang X, Ferrajoli A, Kadia M T, Thompson A P, Alvarado Y, Jain N, Yilmaz M, Khoury D J, Jorgensen L J, Sa WA, Kornblau M S, Konopleva M, Garcia - Manero G, Schroeder M H, Kwari M, Paul S, Nwakanme B, Loiselle C, Garris R, O'Brien M S, Jabbour E. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. 62nd Annual Meeting & Exposition. Blood 136(Suppl 1):9-11, 2020. e-Pub 2020.
4. Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver NG, Ohanian MN, DiNardo CD, Estrov ZE, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour EJ, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce SA, Cortes JE, Konopleva MY, Garcia-Manero G, Ravandi F. Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood 132(Suppl 1):84, 2018. e-Pub 2018.
5. Rausch CR, Paul S, Bravo GM, Jabbour EJ, Daver NG, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Kornblau SM, Cortes JE, Kadia TM, Konopleva MY, Ohanian MN, Pierce SA, Gasior Y, Benton CB, Jain N, Takahashi K, Masarova L, Andreeff M, Estrov ZE, Kantarjian HM, Garcia-Manero G. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood 132(Suppl 1):4367, 2018. e-Pub 2018.
6. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Colla S, Yang H, Rausch CR, Gasior Y, Bueso-Ramos CE, Kanagal-Shamanna R, Patel KP, Kantarjia HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):465, 2018. e-Pub 2018.
7. Garcia-Manero G, Sasaki K, Montalban-Bravo G, Bodden KR, Bose P, Alvarado Y, Daver NG, Borthakur G, Ravandi F, Takahashi K, Cortes JE, Jabbour EJ, Naqvi K, DiNardo CD, Benton CB, Pemmaraju N, Kadia TM, Ohanian MN, Pierce SA, Kantarjian HM. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):232, 2018. e-Pub 2018.
8. Chien KS, Benton CB, Tefferi A, Rodríguez J, Ravandi F, Daver NG, Jabbour EJ, Jain N, Alvarado Y, Kwari M, Pierce SA, Maiti A, Hornbaker MJ, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian HM, Pardanani A, Garcia-Manero G. Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 132(Suppl 1):2722, 2018. e-Pub 2018.
9. Short NJ, Jabbour EJ, Ravandi F, Huang X, Jain N, Sasaki K, Pemmaraju N, Daver NG, Khoury JD, Jorgensen JL, Alvarado Y, Konopleva MY, Garcia-Manero G, Kadia TM, Yilmaz M, Borthakur G, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Nasnas P, Jacob J, Garris RE, O'Brien SM, Kantarjian HM. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood 132(Suppl 1):36, 2018. e-Pub 2018.
10. Garcia-Manero G, Kurman MR, DiNardo CD, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour EJ, Delumpa R, Madden T, Maier G, Iwamura H, Kantarjian HM. Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):1438, 2018. e-Pub 2018.
11. Navada SC, Garcia-Manero G, Atallah EL, Rajeh M, Shammo JM, Griffiths EA, Khaled SK, Dakhil SR, Young DE, Odchimar-Reissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Zbyszewski PS, Maniar M, Petrone ME, Fruchtman SM, Silverman LR. Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients. Blood 132(Suppl 1):259, 2018. e-Pub 2018.
12. Aboudalle I, Kantarjian HM, Ohanian MN, Alvarado Y, Jabbour EJ, Garcia-Manero G, Naqvi K, Wierda WG, Daver NG, Burger JA, Konopleva MY, Takahashi K, Andreeff M, Pemmaraju N, Ferrajoli A, Borthakur G, Kadia TM, Ravandi F, Cortes JE. Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. Blood 132(Supple 1):2715, 2018. e-Pub 2018.
13. Daver NG, Garcia-Manero G, Basu S, Cortes JE, Ravandi F, Kadia TM, Konopleva MY, Jabbour EJ, DiNardo CD, Assi R, Yesid Alvarado SAP, Estrov ZE, Pemmaraju N, Takahashi K, Ning J, Nogueras González GM, Kornblau SM, Alfayez M, Matthews J, Flores W, Blando J, Allison JP, Sharma P, Kantarjian HM. Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood 132(Suppl 1):906, 2018. e-Pub 2018.
14. Ravandi F, Pierce SA, Garcia-Manero G, Kadia TM, Jabbour EJ, Borthakur G, DiNardo CD, Daver NG, Short NJ, Alvarado Y, Cortes JE, Kim C, Kelsh MA, Katz AJ, Williams R, Yang Z, Mehta B, Kantarjian HM. Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood 132(Suppl 1):3985, 2018. e-Pub 2018.
15. Bose P, McCue D, Wiederhold NP, Kadia TM, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson PA, Pemmaraju N, Daver NG, Burger JA, Cortes JE, Garcia-Manero G, Verstovsek S, Konopleva MY, Jain N, DiNardo CD, Alvarado Y, Naqvi K, Kornblau SM, Ferrajoli A, Wierda WG, Estrov ZE, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 132(Suppl 1):2674, 2018. e-Pub 2018.
16. Aboudalle I, Kantarjian HM, Short NJ, Khouri M, Takahashi K, Ohanian MN, Borthakur G, Konopleva MY, Daver NG, Estrov ZE, Alvarado Y, Jain N, Ravandi F, Garcia-Manero G, Velasquez M, Nasnas P, O'Brien SM, Jabbour EJ. Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease. Blood 132(Suppl 1):5212, 2018. e-Pub 2018.
17. Maiti A, DiNardo CD, Cortes JE, Borthakur G, Pemmaraju N, Benton CB, Kadia TM, Takahashi K, Naqvi K, Ravandi F, Alvarado Y, Short NJ, Daver NG, Sasaki K, Ohanian MN, Garcia-Manero G, Thompson PA, Kornblau SM, Masarova L, Jain N, Jabbour EJ, Andreeff M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Rausch CR, Bivins CA, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 132(Suppl 1):286, 2018. e-Pub 2018.
18. Assi R, Kantarjian HM, Daver NG, Garcia-Manero G, Benton CB, Thompson PA, Borthakur G, Kadia TM, Alvarado Y, Jabbour EJ, Konopleva MY, Takahashi K, Kornblau SM, DiNardo CD, Estrov ZE, Flores W, Basu S, Allison JP, Sharma P, Pierce SA, Pike A, Cortes JE, Ravandi F. Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):905, 2018. e-Pub 2018.
19. Garcia-Manero G, Montalban-Bravo G, Sasaki K, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Rausch CR, Gasior Y, Kantarjian HM. You have access Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 132(Suppl 1):1831, 2018. e-Pub 2018.
20. Bannon S, Routbort M, Garcia-Manero G, Daver NG, Oran B, Borthakur G, Mehta RS, Naqvi K, Takahashi K, Alvarado Y, Kadia TM, Kantarjian HM, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Blood 132(Suppl 1):2667, 2018. e-Pub 2018.
21. Benton C, - Pavon JRD, Maiti A, Daver N, Ravandi F, Jain N, Alvarado Y, Jabbour E, Pierce S, Kwari M, Santos MA, Martinez S, Siguero M, Tefferi A, Cortes JE, Kantarjian H, Pardanani AD, - Manero GG. Phase I study of lurbinectedin (PM11083) in patients with advanced AML and MDS. Journal Of Clinical Oncology, 2017. e-Pub 2017.
22. Naqvi K, - Gonzalez GMN, Cheung CM, Pemmaraju N, Jabbour E, - Manero GG, DiNardo C, Ohanian M, Jain N, Takahashi K, Alvarado Y, Konopleva M, Xue, Huang O, Cortes JE, Kantarjian H. A bayesian randomized phse II study of guadecitabine (SGI-110) based regimens comparing guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5 = Ida), 5 days + cladribine(SGI5+ Clad), in untreated patien >/= 70years with acute myeloid leukemia (AML). Journal Of Clinical Oncology, 2017. e-Pub 2017.
23. . Updated results frp, phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Journal Of Clinical Oncology, 2017. e-Pub 2017.
24. Short N, Kantarjian H, O'Brien SM, Ravandi F, Thomas DA, - Manero GG, Daver N, Borthakur G, Jain N, Konopleva M, Sasaki K, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson PA, Cortes JE, Jabbour E. Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low - intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. Journal Of Clinical Oncology, 2017. e-Pub 2017.
25. boddu P, Jorgenson JL, Kantarjian H, Borthakur G, Kadia T, Daver NG, Alvarado Y, Pemmarju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo C, Jabbour E, - Manero GG, Cortes JE, Ravandi F. Achievement of a negative minimak residual disease state after hypomethylating agent therapy in older patients with AML to reduce risk of relapse. Journal Of Clinical Oncology, 2017. e-Pub 2017.
26. Ohanian M, Ravandi F, Borthakur G, Manero GG, Andreeff M, Jabbour E, Alvarado Y, Konopleva M, Sherry Pierce ML, O'Brien SM, Ashizawa AT, Verstovsek S, Wierda WG, Cortes JE. Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies. Journal Of Clinical Oncology, 2016. e-Pub 2016.
27. Jain P, Kantrajian H, Ravandi F, Jabbour E, Daver N, Pemmaraju N, DiNardo CD, Alvarado Y, Jain N, Borthakur G, Verstovsek S, Ferrjoli A, Ohanian M, Konopleva M, Naqvi K, Fitch T, - Manero GG, Cortes JE, Estrov Z, Kadia TM. Cladribine Combined with Idarubicin and Ara - C (CLIA) as a Frontline and Salvage Treatment for Young Patients (
28. . A Clinical Study of OPN - 305, a Toll - like Receptor 2 (TLR-2) Antibpdy, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy. Blood, 2016. e-Pub 2016.
29. Navada SC, manero GG, Hearn KP, P Demakos RO-RE, Alvarado Y, Daver N, DiNardo CD, Konopleva M, Borthakur G, Fenaux P, Petrone ME, Zbyszewski PS, Fruchtman SM, Silverman L. Combination of Oral Rigosertib and Injectable Azacitidine in Patient with Myelodysplastic Syndromes (MDS): Results from a Phase || Study. Blood, 2016. e-Pub 2016.
30. Sasaki K, Jabbour E, O'Brien SM, Ravandi F, Thomas DA, - Manero GG, Daver N, Borhtakur G, Jain N, Konolpeva M, Short NJ, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson PA, Cortes J, Kantarjian H. Inotuzumab Ozogamicin in Combination with Low- Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patiens with Acute Lymphoblastic Leukemial (ALL): Interim Result of a Phase || Clinical Trial. Blood, 2016. e-Pub 2016.
31. Navada SC, Silverman LR, Hearn KP, - Reissig RO, Demakos EP, Alvarado Y, Daver N, DiNardo C, Konopleva M, Borthakur G, Pemmaraju N, Kadia T, Fenaux P, Fruchtman S, Azarnia N, - Manero GG. A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS). Blood, 2016. e-Pub 2016.
32. Jain N, Ravandi F, - Manero GG, Borthakur G, Kadia TM, Jabbour EJ, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Alvardao Y, Takahashi K, Benton CB, Pike A, Pierce S, Cortes JE, Kantarjian H. Decitabine Followed By Clofarabine, Idarubicin, and Cytatabine (DAC- CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2016. e-Pub 2016.
33. Sasaki K, Jabbour E, O'Brien S, Rvandi F, Thomas DA, Kadia T, - Manero GG, Burger JA, Pemmaraju N, Alvarado Y, Daver N, Jain N, Konopleva M, Champlin RE, Khouri IF, Jacob J, Garris R, Cortes JE, Kantarjian H. Phase II Study of the Salvage Mini - Hyper - CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute lymphoblastic Leukemia (ALL). Blood, 2016. e-Pub 2016.
34. Jabbour E, Short NJ, Huang X, maiti A, Kadia TM, Daver N, Borthakur G, DiNardo CD, Pemmaraju N, Sasaki K, Estrov Z, Verstovsek S, Ravandi F, Alvarado Y, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Miller D, Dong X, Kantarjian H, - Manero GG. A Ramdomized Phase II Study of Low - Dose Decitabine Versus Azacitidine in Patients with Low - or Intermediate - 1 - Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2016. e-Pub 2016.
35. Bravo GM, Bose P, Alvarado Y, Daver N, Ravandi F, Borthakur G, Takahashi K, Andreeff M, Cortes JE, DiNardo CD, Jabbour E, Kadia TM, Kornblau S, Ohanian M, Pierola AA, Hauang X, - Gonzalez GMN, Bodden K, Littles K, Pierce S, - Ramos CEB, Kantarjian H, - Manero GG. Initial Results of a Phase 2 Study of Guadecitabine (SGI - 110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate - 2 or High Risk myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2016. e-Pub 2016.
36. Short N, - Manero GG, Naqvi K, Kornblau S, Nautu A, Konopleva M, DiNardo CD, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong X, Cortes JE, Kantarjian H, Jabbour E. A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High - Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood, 2016. e-Pub 2016.
37. Saski K, Kantarjian H, Ravandi F, Daver N, Kadia TM, Khouri RB, Alvarado Y, Burger JA, Thomas DA, - Manero GG, DiNardo CD, Pemmaraju N, Short NJ, Schroeder H, Garris R, Bose P, Jain N, Naqvi K, Wierda WG, Verstovsek S, Cortes JE, Konpleva M, O'Brien SM, Jabbour E. Frontline Ofatumumab in Combination with Hyper - CVAD for Adult Patients with CD - Postive Acute Lymphoblastic leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood, 2016. e-Pub 2016.
38. Khan M, Kantarjian H, - Manero GG, Borthakur G, Kadia T, Huang X, Daver N, DiNardo CD, Ferrajoli A, Wierda W, Estrov Z, Benton C, Bose P, Alvardo Y, Kornblau S, Ohanian M, Gasior Y, Richie MA, Pierce S, Jabbour E, Cortes JE, Ravandi F. Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligble for Standrad Cytotoxic Induction Regimens. Blood, 2016. e-Pub 2016.
39. . A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia. Blood, 2016. e-Pub 2016.
40. . A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood, 2016. e-Pub 2016.
41. Bose P, Verstovsek S, Gasior Y, Jain N, Jabbour E, Etrov Z, Alvarado Y, DiNardo CD, M Kornblau NPS, Kadia TM, Daver NG, Brandt M, Pierce S, - Gonzalez GMN, Huang X, - Manero GG, Kantarjian H, Ravandi F. Phase I/II Study of Ruxolitinib (RUX) wutg Decutabine (DAC) in Patients with Post - Myeloproliferative Neoplasm Acute Myeloid Leukemia (post - MPN AML): Phase I Results. Blood, 2016. e-Pub 2016.
42. Khan M, Bodden K, Kadia T, Ferrajoli A, Alvarado Y, Borthakur G, Pemmaraju N, Konopleva M, - Manero GG, DiNardo C. Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating - Agent Failure: A Phase 2 Clinical Trial. Blood, 2015. e-Pub 2015.
43. Kadia T, Cortes JE, Jabbour E, Daver N, Pemmarju N, Ravandi F, Jain N, Verstovsek S, DiNardo C, Alvarado Y, Ferrajoli A, Burger JA, - Manero GG, Ohanian M, Konopleva M, Estrov Z, Wierda W, Brandt M, Fitch T, Borthakur G, Kantarjian H. Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood, 2015. e-Pub 2015.
44. . A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML of High - Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. Blood, 2014. e-Pub 2014.
45. Patel K, Routbort M, - Gonzalez GN, Kantarjian H, Jabbour E, Borthakur G, DiNardo CD, Estrov Z, Daver NG, Wierda WG, Jain N, Brien SO, Konopleva M, Cortes JE, Pemmaraju N, Alvarado Y, - Ramos CEB, Luthra R, Singh R, Pierce S, Medeiros L, Bohannan Z, Huang X, - Manero GG. Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. Blood, 2014. e-Pub 2014.
46. Alvarado Y, Keating MJ, Brien SO, Kantarjian H, Wierda WG, Sneed T, Jain N, - Manero GG. Azacytidine and Vorinostat in patient with Chronic Lymphocytic Leukemia (CLL) Diagnosed with Therapy - Related Myelodysplastic Syndromes/Acute Myeloid Leukemia (t- MDS/AML). Blood, 2014. e-Pub 2014.
47. Navada SC, - Manero GG, Wilhelm F, Hearn K, - Reissig RO, Demakos EP, Alvarado Y, Daver N, DiNardo CD, Konopleva M, Borthakur G, Azarnia N. A Phase I/Ii Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemai (AML). Blood, 2014. e-Pub 2014.
48. Kornblau SM, Hu CW, Qiu Y, Yoo SY, Murray RA, Jain N, Alvarado Y, Coombes K, Qutub AA. Expression of Ribosomal Protein S6 (R6SP) and Eukaryotic translation Initiation Factor 4E Binding Protein 1 (EIEBPF) Is Correlated in Acute Myelogenous Leukemia (AML) and is Highly Prognostic, Especially in NPM1 and FLT3 Wildtype Patients. Blood, 2014. e-Pub 2014.
49. Duque AD, randhawa J, Kantarjian H, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, estrov Z, Konopleva M, Ravandi F, Alvarado Y, Gandhi V, Borthakur G, Cortes JE. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory/Relapsed AML. Blood, 2014. e-Pub 2014.
50. Alvarado Y, Kantarjian H, Ravandi F, Luthra R, Borthakur G, Garcia - Manero G, Faderl S, Konopleva M, Estrov Z, Andreeff M, Cortes J. FLT3 Inhibitor treatment in FLT3-mutated AML is Associated with development of secondary FLT3-TKD mutations. 53rd ASH Annual Meeting. Blood 118, 2011. e-Pub 2011.
51. Liu - Dumlao T, Kantarjian H, Quintas - Cardama A, Jabbour E, Burger J, Alvarado Y, Burton E, Trinh L, Ravandi F, Ferrajoli A, O'Brien S, Cortes J. Clinical significance of myelosuppression associated with the use of Dasatinib and Nilotinib as initial therapy in chronic phase of Chronic Myeloid Leukemia. 53rd ASH Annual Meeting. Blood 118, 2011. e-Pub 2011.
52. Alavarado Y, Kantarjian H, Ravandi F, Luthra R, Borthakur G, - Manero GG, Faderl S, Konopleva M, Estrov Z, Andreeff M, Cortes JE. FLT3 Inhibitor Treatment in FLT3 - Mutated AML is Associated with Development of Secondary FLT3 - TKD Mutations. Blood, 2011. e-Pub 2011.
53. . Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML). Blood, 2011. e-Pub 2011.
54. Ault P, Kantarjian H, Bryan J, Prescot H, Y A, Fava C, Cortes J. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia. 48th ASH Annual Meeting. Blood 112:4255, 2008. e-Pub 2008.
55. Alvarado Y, Kantarjian H, Verma D, Mattiuzzi G, Aribi A, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoiesis-stimulating agents (ESA) in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib. 49th ASH Annual Meeting, 2007. e-Pub 2007.
56. Alvarado Y, Kantarjian H, Faderl S, Burger J, Borthakur G, O’Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML). 49th ASH Annual Meeting, 2007. e-Pub 2007.
57. Alvarado Y, Kantarjian H, Freireich EJ, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau S, Laddie N, Smith L, Cortes J. Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML). ASCO National Annual Meeting, 2007. e-Pub 2007.
58. Alvarado Y, Brown R, DiPiersio J, Verstovsek S, Cortes J, O’Brien S, Sznol M, Kantarjian H, Fracasso P, Giles F. Phase I study of Triapine, a novel ribonuclotide reductase inhibitor (RRI), in patients with refractory hematologic malignancies. 44th ASH Annual Meeting. Leukemia Research 27(12):1077-1083, 2003. e-Pub 2003.
59. Alvarado Y, Kantarjian H, Cortes J, Verstovsek S, Faderl S, Garcia-Manero G, Tsimberidou A, Sznol M, Giles F. Phase I Study of VNP40101M, a novel alkylating agent in patients with refractory hematologic malignancies. ASCO National Annual Meeting, 2003. e-Pub 2003.
60. Waddelow T, Mattiuzzi G, Alvarado Y, Giles F, Estey E. Rate of infections Associated with Gemtuzumab (GO) vs. Non-Gemtuzumab Therapy in patients with Acute Myelogenous Leukemia (AML) or myelodysplastic Syndrome (MDS), 2001. e-Pub 2001.
61. Waddelow T, Mattiuzzi G, Alvarado Y, Giles F, Estey E. Rate of infections Associated with Gemtuzumab (GO) vs. Non-Gemtuzumab Therapy in patients with Acute Myelogenous Leukemia (AML) or myelodysplastic Syndrome (MDS). 43rd ASH Annual Meeting, 2001. e-Pub 2001.

Letters to the Editor

1. Swaminathan, M, DiNardo, C, Maiti, A, Pemmaraju, N, Ohanian, M, Daver, NG, Garcia-Manero, G, Issa, GC, Borthakur, G, Ravandi-Kashani, F, Montalban Bravo, G, Kadia, TM, Alvarado, Y, Jabbour, EJ, Short, NJ, Wierda, WG, Jain, N, Kornblau, SM, Masarova, L, Pierce, S, Qiao, W, Ning, J, Kantarjian, HM, Konopleva, M. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome. Blood cancer journal 15, 2025.
2. Bouligny, IM, MontalbanBravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Bose, P, Pemmaraju, N, Kornblau, SM, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, KanagalShamanna, R, Hosing, C, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110: 1628-1633, 2025.
3. Senapati, J, Garcia-Manero, G, DiNardo, C, Deshmukh, I, Borthakur, G, Kadia, TM, Jabbour, EJ, Short, NJ, Abbas, HA, Pemmaraju, N, Jain, N, Haddad, FG, Issa, GC, Maiti, A, Shpall, E, Popat, UR, Loghavi, S, Tang, G, Yilmaz, M, Alvarado, Y, Montalban Bravo, G, Ravandi-Kashani, F, Kantarjian, HM, Daver, N. Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia. Bone marrow transplantation 60: 910-913, 2025.
4. Bouligny, IM, Montalban-Bravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, CD, Ravandi, F, Borthakur, G, Pemmaraju, N, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, Kanagal, R, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39: 524-528, 2025.
5. Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38: 2717-2721, 2024.
6. Chien, KS, Rodriguez-Sevilla, JJ, Alvarado, Y, Montalban-Bravo, G, Hammond, DE, Swaminathan, M, Bazinet, A, Kimberley, J, Bodden, K, Schneider, H, Dong, XQ, Pierce, S, Huang, X, Jabbour, EJ, Kantarjian, H, Garcia-Manero, G. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. Leukemia Research 147, 2024.
7. Bose, P, Masarova, L, Pemmaraju, N, Bledsoe, S, Daver, N, Jabbour, EJ, Kadia, TM, Estrov, Z, Kornblau, SM, Andreeff, M, Jain, N, Cortes, JE, Borthakur, G, Alvarado, Y, Richie, MA, Dobbins, MH, McCrackin, SA, Zhou, L, Pierce, S, Wang, X, Pike, A, Garcia-Manero, G, Kantarjian, H, Verstovsek, S. Sotatercept for anemia of myelofibrosis. Haematologica 109: 2660-2664, 2024.